Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kubiet, M. A.
Right arrow Articles by Bender, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kubiet, M. A.
Right arrow Articles by Bender, B. S.
(Chest. 1996;110:367-370.)
© 1996 American College of Chest Physicians

Serum Antibody Response to Influenza Vaccine in Pulmonary Patients Receiving Corticosteroids

Martin A. Kubiet MD1; Ricardo J. Gonzalez-Rothi MD, FCCP1; Rob Cottey BS2; and Bradley S. Bender MD2

1 From the Division of Pulmonary Medicine, University of Florida College of Medicine and Gainesville VAMC and the Geriatric Research and Education Center VAMC, Gainesville, Fla.
2 From the Division of Infectious Diseases, University of Florida College of Medicine and Gainesville VAMC and the Geriatric Research and Education Center VAMC, Gainesville, Fla.

Objective: Despite the recommendation that patients with chronic lung diseases—many of whom receive corticosteroids—receive annual influenza vaccination, it is not known whether corticosteroids influence antibody response to influenza vaccine in this population. The purpose of this study was to assess whether patients with pulmonary conditions receiving long-term corticosteroid therapy develop an adequate antibody response.

Design: We prospectively studied 39 consecutive candidates for influenza vaccination, 25 of whom were receiving corticosteroids for underlying lung diseases. Patients with immunosuppression besides corticosteroids were excluded. Serum samples were obtained prior to and 1 month after vaccination with inactivated trivalent influenza vaccine and assayed for antibodies to the three strains using a hemagglutination inhibition assay. No patients had any intercurrent illness compatible with influenza during the study period and patients receiving corticosteroids continued treatment with them during this time.

Results: A fourfold rise in antibody titer at 1 month to at least one component was seen in 21 of 25 (84%) of corticosteroid-treated patients, which was similar to patients not receiving corticosteroids (11/14, 79%). There was no corticosteroid-antibody, dose-response relationship.

Conclusions: Patients with pulmonary conditions receiving corticosteroids can generate an adequate antibody response to killed influenza virus vaccine. Long-term therapy with corticosteroids should not preclude influenza vaccination in patients with chronic pulmonary diseases who are deemed vaccine candidates.

Key Words: antibody response • corticosteroids • influenza vaccine • pulmonary disease

Submitted on August 29, 1995
Accepted on February 7, 1996




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
E. Oken, D. L. Kasper, R. E. Gleason, and G. K. Adler
Tetanus Toxoid Stimulation of the Hypothalamic-Pituitary-Adrenal Axis Correlates Inversely with the Increase in Tetanus Toxoid Antibody Titers
J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1691 - 1696.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Chest Physicians.